Carrie Pedersen
Family · Edgewood, TXNPI 1093203861
Payments from drug & device makers
Across 127 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$686
- Amarin Pharma, Inc.$210
- Novo Nordisk$204
- Boehringer Ingelheim$152
- Amgen$94
- AstraZeneca$70
- plus $688 from 18 others
What the payments were for
- Food & beverage$2,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $686 |
| Amarin Pharma, Inc. | 12 | $210 |
| Novo Nordisk | 13 | $204 |
| Boehringer Ingelheim | 9 | $152 |
| Amgen | 5 | $94 |
| AstraZeneca | 5 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Merck | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 5 | $65 |
| Lilly USA, LLC | 4 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| GSK | 4 | $54 |
| Antares Pharma, Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Abbott | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Pfizer | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,103 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $20,373 |
| EliquisApixaban | 22 | $19,098 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $730 |
| Gabapentin | 28 | $627 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $333 |
| Omeprazole | 18 | $331 |
| Atorvastatin Calcium | 51 | $330 |
| Amlodipine Besylate | 24 | $253 |
| Hydroxyzine Hcl | 14 | $246 |
| Escitalopram Oxalate | 23 | $229 |
| Losartan Potassium | 28 | $221 |
| Sertraline Hcl | 26 | $205 |
| Levothyroxine Sodium | 25 | $203 |
| Pantoprazole Sodium | 23 | $197 |
| Trazodone Hcl | 14 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $204 | $20,37314 claims |
| PfizerEliquis | $17 | $19,09822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Edgewood
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.